home / lobbying

lobbying_activities

Individual lobbying activities reported in quarterly filings. Each row is one issue area for one client — includes the specific issues lobbied on, government entities contacted, and income/expense amounts.

Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API

284 rows where filing_period = "second_quarter", filing_year = 2023 and issue_code = "PHA" sorted by filing_year descending

✎ View and edit SQL

This data as json, CSV (advanced)

Suggested facets: filing_type, income_amount, is_termination, received_date (date)

issue_code 1

  • PHA · 284 ✖

filing_year 1

  • 2023 · 284 ✖

filing_period 1

  • second_quarter · 284 ✖
id filing_uuid filing_type registrant_name registrant_id client_name filing_year ▲ filing_period issue_code specific_issues government_entities income_amount expense_amount is_no_activity is_termination received_date
2957575 PARDES BIOSCIENCES, INC. 7b178cfd-76ff-4ab0-bfa0-f3bee1a34931 2T PARDES BIOSCIENCES, INC. 401106493 PARDES BIOSCIENCES, INC. 2023 second_quarter PHA Physician prescribing of covid antivirals Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,Office of Science & Technology Policy (OSTP),SENATE   120000 0 1 2023-04-12T10:26:43-04:00
2998027 THORN RUN PARTNERS 50a8b457-7284-48c9-a8b3-244cec6c6c49 2T THORN RUN PARTNERS 400534596 HUMANITY FORWARD 2023 second_quarter PHA Issues and legislation related to reduction of prescription medication for Americans. HOUSE OF REPRESENTATIVES,SENATE,White House Office 40000   0 1 2023-06-27T10:06:23-04:00
2998122 MCDERMOTT+ LLC e7af16b4-d06b-4230-bc30-05d781846aea Q2 MCDERMOTT+ LLC 401103287 ALLIANCE FOR RURAL HOSPITAL ACCESS 2023 second_quarter PHA Amendments to Section 340B of the Public Health Service Act regarding eligibility for rural referral centers and sole community hospitals in the federal discount drug purchasing program. HOUSE OF REPRESENTATIVES,SENATE 60000   0 0 2023-06-29T13:33:07-04:00
2998483 RED+BLUE STRATEGIES a3205bf6-0e40-485b-bd67-4cc4aa7b6c97 Q2 RED+BLUE STRATEGIES 400693064 PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION (PCMA) 2023 second_quarter PHA S. 1967 - The PBM Act - Issues related to delinking and limiting current tools used by PBMS to manage pharmacy benefits in Medicare. S. 1339 - The Pharmacy Benefit Manager Reform Act - Issues focused on limiting spread pricing and requiring rebate pass through and other tools used to control the price of prescription medications. S. 127 - The PBM Transparency Act - Issues related to the study of Pharmacy Benefit Managers by the Federal Trade Commission. S. 150 - Affordable Prescriptions for Patients Act - Issues related to ensuring that people's access to affordable medications are not impeded and innovations to ensure fair pricing structures are promulgated to their fullest. Issues related to prescription drug supply chain integrity and transparency. Issues related to the implementation of the Inflation Reduction Act for purposes of ensuring access to affordable medications for Medicare beneficiaries and people across the United States. Executive Office of the President (EOP),HOUSE OF REPRESENTATIVES,SENATE 70000   0 0 2023-07-04T11:49:42-04:00
2998857 EMERGENT STRATEGIES 93f06a6f-4f89-4219-9538-90044c2a2108 Q2 EMERGENT STRATEGIES 401104778 GENBIOPRO, INC. 2023 second_quarter PHA FDA Approval of generic mifepristone and related Risk Evaluation Mitigation Strategies (REMS). HOUSE OF REPRESENTATIVES,SENATE 35000   0 0 2023-07-05T10:32:58-04:00
2999110 RED+BLUE STRATEGIES da91088d-6cdc-4e5b-ba56-6d844aa70e14 Q2 RED+BLUE STRATEGIES 400693064 COHERUS BIOSCIENCES 2023 second_quarter PHA Issues related to drug shortages in the United States and the role biosimilars can play. Issues related to cancer care and developing both biosimilar and novel treatments to fight disease. Issues related to advancing biosimilars in the health care market place to increase access and efficacy of life saving drugs. Support for encouraging the development, manufacturing and distribution of American-made biosimilars and other related products. Executive Office of the President (EOP),HOUSE OF REPRESENTATIVES,SENATE 50000   0 0 2023-07-05T19:04:30-04:00
2999113 STONINGTON GLOBAL d2c21b73-b3f1-415a-bdc2-e63cf8a56fbb Q2 STONINGTON GLOBAL 401105189 SORRENTO THERAPEUTICS, INC. 2023 second_quarter PHA Promoting non-opioid pain management alternatives. Executive Office of the President (EOP),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE,White House Office     0 0 2023-07-05T19:16:07-04:00
2999135 AMERICAN COLLEGE OF CLINICAL PHARMACY 1dcbc5ab-ac19-4621-ad46-7057ddea9c82 Q2 AMERICAN COLLEGE OF CLINICAL PHARMACY 57258 AMERICAN COLLEGE OF CLINICAL PHARMACY 2023 second_quarter PHA Coverage for direct patient care services of qualified clinical pharmacists under Medicare and other public health programs. HOUSE OF REPRESENTATIVES,SENATE   144981 0 0 2023-07-06T04:40:27-04:00
2999300 REPUBLIC CONSULTING, LLC 09db606d-59fe-4cca-9856-be82ae11a84b Q2 REPUBLIC CONSULTING, LLC 401016871 IQVIA 2023 second_quarter PHA Monitor Health Data Policy. Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE 60000   0 0 2023-07-06T11:42:46-04:00
2999333 DAVE KOLBE CONSULTING 682920dd-ec16-481a-a2f1-4d5d7e768bf2 Q2 DAVE KOLBE CONSULTING 401104329 PHARMACEUTICAL INDUSTRY LABOR MANAGEMENT ASSOCIATION 2023 second_quarter PHA H.R. 830 HELP COPAYS ACT - Urging support of the Help Copays Act to ensure affordable access to life-saving medications for all Americans. Provide relief to patients by capping copayments for prescription drugs. S. 1246 SMART PRICES ACT - Urging opposition to the SMART legislation. The emphasis on price controls for prescription drug price negotiations would have adverse effects on future research, investments, and empllyment opportunites in our country. H.R. 3694 WTO'S Expansion of TRIPS Waivers for Drugs - Urging opposition of the waiver to COVID-19 diagnostic devices and treatments, as many WTO members are proposing, would endanger American jobs without improving global health. HOUSE OF REPRESENTATIVES,SENATE 30000   0 0 2023-07-06T12:35:51-04:00
2999596 PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION 23fb37e5-6f2a-4dfb-b000-cbefcb617ca0 Q2 PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION 401103605 PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION 2023 second_quarter PHA Discussed issues related to drug shortages, pandemic preparedness, workforce development, advanced manufacturing, and onshoring HOUSE OF REPRESENTATIVES,SENATE   50000 0 0 2023-07-07T09:44:31-04:00
3000073 4C COMMUNICATIONS, INC. 16202ca1-673a-45f7-a121-066a84644085 Q2 4C COMMUNICATIONS, INC. 323717 HEALTHCARE LEADERSHIP COUNCIL 2023 second_quarter PHA Medicare Advantage HOUSE OF REPRESENTATIVES,SENATE     0 0 2023-07-09T11:34:40-04:00
3000498 PENN AVENUE PARTNERS 68bf36ca-68a4-466e-8c98-ade3926de446 Q2 PENN AVENUE PARTNERS 400918672 ALKERMES, INC. 2023 second_quarter PHA Regulatory and legislative issues impacting Alkermes. Appropriations. HOUSE OF REPRESENTATIVES,SENATE 50000   0 0 2023-07-10T15:36:48-04:00
3000617 PENN AVENUE PARTNERS 90329d10-e2b5-417b-8a6f-39de2804e2b8 Q2 PENN AVENUE PARTNERS 400918672 UNITEDHEALTH GROUP, INC. 2023 second_quarter PHA Pharmacy benefit related issues. Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Office of Management & Budget (OMB),SENATE,White House Office 90000   0 0 2023-07-11T06:22:35-04:00
3000960 FROST BROWN TODD LLC 3a710a7d-8fa8-493a-bc40-c32d7350eaaa Q2 FROST BROWN TODD LLC 283572 DISPOSERX 2023 second_quarter PHA Support Act Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE 10000   0 0 2023-07-11T13:16:16-04:00
3001048 NATIONAL ASSOCIATION OF CHAIN DRUG STORES 7730e925-a96a-460d-b855-4d0870c1b0af Q2 NATIONAL ASSOCIATION OF CHAIN DRUG STORES 26672 NATIONAL ASSOCIATION OF CHAIN DRUG STORES 2023 second_quarter PHA H.R. 1613 Drug Price Transparency in Medicaid Act of 2023 H.R. 1770 The Equitable Community Access to Pharmacist Services Act H.R. 2880 Protecting Patients Against PBM Abuses Act H.R. 2816 The PBM Sunshine and Accountability Act H.R. 3561 The Patient Act S. 113 Prescription Pricing for the People Act S. 127 Pharmacy Benefit Manager Transparency Act S. 1038 Drug Price Transparency in Medicaid Act of 2023 S. 1339 Pharmacy Benefit Manager Reform Act S. 1491 Pharmacy and Medically Underserved Areas Enhancement Act S. 2052 Protect Patient Access to Pharmacies Act HOUSE OF REPRESENTATIVES,SENATE   350000 0 0 2023-07-11T15:13:29-04:00
3001166 MR. H.R. BERT PENA 187335aa-af99-4a4b-88c4-548a9004493d Q2 MR. H.R. BERT PENA 400323519 MARGO RX LLC(DBA RICHARD'S PHARMACY) 2023 second_quarter PHA PBM AND DRUG PRICES Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES     0 0 2023-07-11T16:47:20-04:00
3001232 HOLLAND & KNIGHT LLP f376ed09-b536-4cbe-968c-8642a1596970 Q2 HOLLAND & KNIGHT LLP 18466 VIATRIS INC 2023 second_quarter PHA Increasing Transparency in Generic Drug Applications Act, (S. 775), Part D Formulary Design; Supply Chain Issues, E-labeling; Inflation Reduction Act Implementation, Improving Generic Drug Access, PEPFAR. Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,SENATE 60000   0 0 2023-07-12T07:45:28-04:00
3001307 GAINWELL TECHNOLOGIES (FKA HEALTH MANAGEMENT SYSTEMS) 0838c757-1292-4775-ad38-9868578bb73b Q2 GAINWELL TECHNOLOGIES (FKA HEALTH MANAGEMENT SYSTEMS) 400270236 GAINWELL TECHNOLOGIES (FKA HEALTH MANAGEMENT SYSTEMS) 2023 second_quarter PHA Monitoring PBM discussions (focused on Medicaid) HOUSE OF REPRESENTATIVES,SENATE   8000 0 0 2023-07-12T10:32:48-04:00
3001363 LUNGREN LOPINA LLC 7cba4ccc-1b9c-4c89-99c7-2c6e1152a936 Q2 LUNGREN LOPINA LLC 401103314 AMPAC FINE CHEMICALS 2023 second_quarter PHA Fair treatment for US based pharmaceutical ingredients Drug Enforcement Administration (DEA),HOUSE OF REPRESENTATIVES,SENATE 40000   0 0 2023-07-12T11:59:31-04:00
3001496 NATIONAL COMMUNITY PHARMACISTS ASSOCIATION 4b5df1ae-9188-4aec-bbdb-0b1f1bb36521 Q2 NATIONAL COMMUNITY PHARMACISTS ASSOCIATION 27478 NATIONAL COMMUNITY PHARMACISTS ASSOCIATION 2023 second_quarter PHA H.R. 167, the Patient Access to Urgent-Use Pharmacy Compounding Act of 2023; H.R. 382, the Pandemic is Over Act; H.R. 2679, the Pharmacy Benefits Manager Accountability Act; H.R. 3008, the Drug Shortage Prevention Act; S. 1339, the Pharmacy Benefits Manager Reform Act; S. 1542, the Delinking Revenue from Unfair Gouging Act; Draft legislation, To amend the Public Health Service Act to make updates to the Vaccine Injury Compensation Program; Draft legislation, To amend the Internal Revenue Code of 1986 to provide authority to add additional vaccines to the list of taxable vaccines. Centers For Disease Control & Prevention (CDC),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE   380000 0 0 2023-07-12T13:49:53-04:00
3001698 COUNCIL FOR CITIZENS AGAINST GOVERNMENT WASTE 1093d563-d57f-4677-b3e0-cadc59f6d4a5 Q2 COUNCIL FOR CITIZENS AGAINST GOVERNMENT WASTE 11003 COUNCIL FOR CITIZENS AGAINST GOVERNMENT WASTE 2023 second_quarter PHA CCAGW Urges Senate Health, Education, Labor and Pensions Committee to Oppose S. 1339 SENATE   1100000 0 0 2023-07-12T15:12:10-04:00
3002289 THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH 53672623-3a00-4084-8594-cf0181aa8ee1 Q2 THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH 401104060 THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH 2023 second_quarter PHA Increasing prescription drug affordability and accessibility for people living with Parkinson's via Medicare Part D redesign and benefits, including expanding the low-income subsidy (LIS) program, capping out-of-pocket costs, implementing a smoothing mechanism, and streamlining prior authorization processes. S.652 - Safe Step Act: a bill to require group health plans to provide an exception process for any medication step therapy protocol to help ensure that people living with Parkinson's disease can safely and efficiently access treatments. H.R.830/S.1375 - Help Ensure Lower Patient Copays Act: a bill to require health insurance plans to apply certain payments made by, or on behalf of, a plan enrollee toward a plan's cost-sharing requirements. Specifically, plans must apply third-party payments, financial assistance, discounts, product vouchers, and other reductions in out-of-pocket expenses toward the requirements. Many Parkinson's patients rely on such third-party payments to afford medications to treat and manage their disease symptoms, and this legislation will ensure that all payments whether they come directly out of a pocket or with the help of copay assistance-counts toward out-of-pocket costs of patients. The Medicare Part D Six Protected Classes Policy: requires Part D plan to cover all drugs in six classes: immunosuppressants, antidepressants, antipsychotics, anticonvulsants, antiretrovirals, and antineoplastics. For people living with Parkinson's, most of whom are Medicare beneficiaries, it is essential to have access to wide range of treatment options for antidepressants and antipsychotics. Parkinson's causes non-motor symptoms, including depression and psychosis, and individuals often experience different side effects, reactions, and efficacy based on which medications they take. Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,SENATE   60000 0 0 2023-07-13T10:45:44-04:00
3003232 KOUNTOUPES DENHAM CARR & REID, LLC 52ec1be5-7354-40e0-86fa-5d0ae42f3ca1 Q2 KOUNTOUPES DENHAM CARR & REID, LLC 320918 ABBOTT LABORATORIES 2023 second_quarter PHA Legislation to expand Medicare coverage to permanently include services provided by a pharmacist, including incidental services and supplies, related to testing, drug regimens, and vaccines for COVID-19, influenza, and certain other illnesses, including H.R. 1770, the Equitable Community Access to Pharmacist Services Act. HOUSE OF REPRESENTATIVES,SENATE 60000   0 0 2023-07-13T16:44:46-04:00
3003306 KOUNTOUPES DENHAM CARR & REID, LLC 650c7abe-e655-4b76-8484-30231b749509 Q2 KOUNTOUPES DENHAM CARR & REID, LLC 320918 CENCORA INC. (FORMERLY AMERISOURCEBERGEN CORPORATION) 2023 second_quarter PHA Issues related to the pharmaceutical supply chain, drug shortages, and national stockpiles, including H.R. 405, the Essential Medicines Strategic Stockpile Act of 2023. Legislation that would permanently provide Medicare coverage of services provided by a pharmacist, including incidental services and supplies relating to testing, drug regimens, and vaccines for COVID-19, influenza, and certain other illnesses, including H.R. 1770, The Equitable Community Access to Pharmacist Services Act. HOUSE OF REPRESENTATIVES,SENATE 60000   0 0 2023-07-13T17:07:33-04:00
3004423 MARSHALL & POPP, LLC 98782e6a-8808-4d81-a9ad-00e511c0d67e Q2 MARSHALL & POPP, LLC 401105121 AMGEN USA INC. 2023 second_quarter PHA Issues related to prescription drug value, including implementation of the Inflation Reduction Act (PL 117-169). Issues related to FDA regulation of pharmaceuticals. Issues related to prescription drug pricing and pharmacy benefit manager business practices, including S. 127, Pharmacy Benefit Manager Transparency Act, and H.R. 2679, the PBM Accountability Act. Issues related to the 340B program, including H.R. 3290, to ensure transparency and oversight of the 340B drug discount program. Pandemic All-Hazards Preparedness Act (PAHPA) reauthorization. HOUSE OF REPRESENTATIVES,SENATE 60000   0 0 2023-07-14T15:47:53-04:00
3004477 MARSHALL & POPP, LLC 5ec12dbc-ae37-460b-86d6-5ce5efaba815 Q2 MARSHALL & POPP, LLC 401105121 GENENTECH, INC. 2023 second_quarter PHA Issues related to prescription drug value, including implementation of the Inflation Reduction Act (PL 117-169). Issues related to FDA regulation of pharmaceuticals. Issues related to prescription drug pricing and pharmacy benefit manager business practices, including S. 127, Pharmacy Benefit Manager Transparency Act, and H.R. 2679, the PBM Accountability Act,. Issues related to the 340B program, including H.R. 3290, to ensure transparency and oversight of the 340B drug discount program. Pandemic All-Hazards Preparedness Act (PAHPA) reauthorization. HOUSE OF REPRESENTATIVES,SENATE 60000   0 0 2023-07-14T16:05:24-04:00
3004496 MARSHALL & POPP, LLC 32eaa44d-86e3-4041-aca5-1feeec8676d4 Q2 MARSHALL & POPP, LLC 401105121 PFIZER, INC. 2023 second_quarter PHA Issues related to prescription drug value, including implementation of the Inflation Reduction Act (PL 117-169). Issues related to vaccine development, distribution and injury compensation. Issues related to FDA regulation of pharmaceuticals. Issues related to prescription drug pricing and pharmacy benefit manager business practices, including S. 127, Pharmacy Benefit Manager Transparency Act, and H.R. 2679, the PBM Accountability Act. Issues related to the 340B program, including H.R. 3290, to ensure transparency and oversight of the 340B drug discount program. Pandemic All-Hazards Preparedness Act (PAHPA) reauthorization. HOUSE OF REPRESENTATIVES,SENATE 60000   0 0 2023-07-14T16:12:24-04:00
3004505 MARSHALL & POPP, LLC 386b2b59-e53d-4968-a10b-534bd5aa1224 Q2 MARSHALL & POPP, LLC 401105121 PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA 2023 second_quarter PHA Issues related to prescription drug value, including implementation of the Inflation Reduction Act (PL 117-169). Issues related to vaccine development and distribution. Issues related to insulin pricing. Issues related to FDA regulation of pharmaceuticals. Issues related to prescription drug pricing and pharmacy benefit manager business practices, including S. 127, Pharmacy Benefit Manager Transparency Act, and H.R. 2679, the PBM Accountability Act. Issues related to the 340B program, including H.R. 3290, to ensure transparency and oversight of the 340B drug discount program. Pandemic All-Hazards Preparedness Act (PAHPA) reauthorization. HOUSE OF REPRESENTATIVES,SENATE 40000   0 0 2023-07-14T16:14:46-04:00
3004512 MARSHALL & POPP, LLC 70c2d79f-107a-443d-84ca-1b215c95dfff Q2 MARSHALL & POPP, LLC 401105121 SANOFI U.S. SERVICES, INC. 2023 second_quarter PHA Issues related to prescription drug value, including implementation of the Inflation Reduction Act (PL 117-169). Issues related to vaccine development, distribution and injury compensation. Issues related to insulin pricing. Issues related to FDA regulation of pharmaceuticals. Issues related to prescription drug pricing and pharmacy benefit manager business practices, including S. 127, Pharmacy Benefit Manager Transparency Act, and H.R. 2679, the PBM Accountability Act. Issues related to the 340B program, including H.R. 3290, to ensure transparency and oversight of the 340B drug discount program. Pandemic All-Hazards Preparedness Act (PAHPA) reauthorization. HOUSE OF REPRESENTATIVES,SENATE 60000   0 0 2023-07-14T16:17:25-04:00
3004592 HOGAN LOVELLS US LLP e36e599d-4cd3-44bb-bf88-09463c21db01 Q2 HOGAN LOVELLS US LLP 18422 ALVOGEN, PHARMA US, INC. 2023 second_quarter PHA Issues related to COVID-19 Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE 10000   0 0 2023-07-14T16:39:21-04:00
3004680 ASCENSION HEALTH ALLIANCE D/B/A ASCENSION 13bccf1c-26f8-417a-a055-fa39cca3e397 Q2 ASCENSION HEALTH ALLIANCE D/B/A ASCENSION 401105339 ASCENSION HEALTH ALLIANCE D/B/A ASCENSION 2023 second_quarter PHA 340B Program; Issues related to affordable prescription drugs;H.R. 1770, Equitable Access to Pharmacy Services Act; H.R. 3008, the Drug Shortage Prevention Act; H.R. 3810, the Drug Origin Transparency Act; H.R. 3793, the Ensuring Access to Lifesaving Drugs Act; issues related to preventing and mitigating drug shortages; Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,SENATE   300000 0 0 2023-07-14T17:25:50-04:00
3005155 INDEPENDENT PHARMACY COOPERATIVE d9a329de-4999-4197-99bb-24f6aa91e968 Q2 INDEPENDENT PHARMACY COOPERATIVE 313098 INDEPENDENT PHARMACY COOPERATIVE 2023 second_quarter PHA IPC supports S.127 Pharmacy Benefit Manager Transparency Act of 2023. IPC supports S.113 Prescription Pricing for the People Act of 2023. IPC supports H.R. 1770 Equitable Community Access to Pharmacists Services Act of 2023. IPC supports the Inflation Reduction Act of 2022 and CMS implementation. IPC supports H.R. 1613 Drug Price Transparency in Medicaid Act of 2023. IPC supports S. 1038 Drug Price Transparency in Medicaid Act of 2023 IPC opposes S. 1339 Pharmacy Benefits Reform Act - because it may preempt state PBM laws relating to ERISA. IPC supports H.R. 3561 Promoting Access to Treatments and Increasing Extremely Needed Transparent (PATIENT) Act of 2023 IPC supports S. 1491 Pharmacy and Medically Underserved Areas Enhancement Act Centers For Medicare and Medicaid Services (CMS),Federal Trade Commission (FTC),HOUSE OF REPRESENTATIVES,SENATE   40000 0 0 2023-07-15T15:26:49-04:00
3005306 FORBES-TATE 7c2137b1-a0b0-4891-903c-41fa476c8e07 Q2 FORBES-TATE 400976792 INDEPENDENT PHARMACY COOPERATIVE 2023 second_quarter PHA Issues related to pharmacy regulation, Provider Status, opioid addiction, drug pricing, and Pharmacy Benefit Manager transparency; Issues related to S. 127 - Pharmacy Benefit Manager Transparency Act of 2023, Issues related to S. 1339 - Pharmacy Benefit Manager Reform Act, Issues related to H.R. 3561 - PATIENT Act of 2023. HOUSE OF REPRESENTATIVES,SENATE 30000   0 0 2023-07-15T18:14:43-04:00
3005426 CORNERSTONE GOVERNMENT AFFAIRS, INC. d1ca60a5-ace2-46a9-bd4e-a3b0bf290eed Q2 CORNERSTONE GOVERNMENT AFFAIRS, INC. 75557 CHILDREN'S NATIONAL MEDICAL CENTER 2023 second_quarter PHA Health-related issues including reimbursement, research, public-health & clinical care. Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE 50000   0 0 2023-07-15T22:49:17-04:00
3005542 FORBES-TATE 94323d03-5f40-4def-959a-1777b50eec88 Q2 FORBES-TATE 400976792 PHRMA 2023 second_quarter PHA Issues pertaining to prescription drug pricing; Issues related to the implementation of H.R. 5376 - Inflation Reduction Act of 2022 (P.L. 117-169). HOUSE OF REPRESENTATIVES,SENATE 80000   0 0 2023-07-16T10:45:24-04:00
3005726 FORBES-TATE 40e0438d-caea-410c-b931-a58bc358b4c6 Q2 FORBES-TATE 400976792 CALIFORNIA LIFE SCIENCES ASSOCIATION 2023 second_quarter PHA Issues related to the life sciences industry; Issues related to drug pricing; Issues related to the implementation of H.R. 5376 - Inflation Reduction Act of 2022 (P.L. 117-169). HOUSE OF REPRESENTATIVES,SENATE 40000   0 0 2023-07-16T12:38:22-04:00
3005821 CORNERSTONE GOVERNMENT AFFAIRS, INC. a77f3f72-86cf-4895-b226-0202000dc1a0 Q2 CORNERSTONE GOVERNMENT AFFAIRS, INC. 75557 MICHIGAN HEALTH & HOSPITAL ASSOCIATION 2023 second_quarter PHA Advised on FY 24 Labor-Health and Human Services-Education appropriations; Medicare reimbursement; Medicaid coverage; health care workforce issues; Rural Emergency Hospital designation; and cancer drug shortages. Engaged with Michigan congressional delegation offices. HOUSE OF REPRESENTATIVES,SENATE 50000   0 0 2023-07-16T14:44:07-04:00
3005839 PORT SIDE STRATEGIES, LLC 57477cbd-1c6d-438d-98e4-544a0a70d7a5 Q2 PORT SIDE STRATEGIES, LLC 401105394 SOCIAL SECURITY WORKS 2023 second_quarter PHA Issues related to implementation of the drug pricing provisions of the Inflation Reduction Act of 2022. HOUSE OF REPRESENTATIVES,SENATE 20000   0 0 2023-07-16T14:58:00-04:00
3005841 PORT SIDE STRATEGIES, LLC b3860da1-d311-4999-a41f-76a8976b954a Q2 PORT SIDE STRATEGIES, LLC 401105394 NEW VENTURE FUND 2023 second_quarter PHA Issues related to implementation of the drug pricing provisions of the Inflation Reduction Act of 2022. H.R.485 - Protecting Health Care for All Patients Act of 2023 - opposed. S. 1264 - SMART Prices Act - in support. S. 1323 - End Price Gouging for Medications Act - in support. S. 2157 - A bill to repeal prescription drug price control provisions of the Inflation Reduction Act - opposed. S. 1339 - Pharmacy Benefit Manager Reform Act - in support. S. 1214 - RARE Act - in support. S. 1114 - Expanding Access to Low-Cost Generics Act of 2023 - in support. S.1067 - Ensuring Timely Access to Generics Act of 2023 - in support. HOUSE OF REPRESENTATIVES,SENATE     0 0 2023-07-16T15:00:08-04:00
3005850 PORT SIDE STRATEGIES, LLC fbc6f89e-3ed4-4a69-8894-7574069bc897 Q2 PORT SIDE STRATEGIES, LLC 401105394 CENTER FOR HEALTH AND DEMOCRACY 2023 second_quarter PHA Issues related to implementation of the drug pricing provisions of the Inflation Reduction Act of 2022. S. 1323 - End Price Gouging for Medications Act - in support. S. 1339 - Pharmacy Benefit Manager Reform Act - in support. HOUSE OF REPRESENTATIVES,SENATE 10000   0 0 2023-07-16T15:03:05-04:00
3006746 RICCHETTI INCORPORATED 31ccf3cf-9283-4f87-bb19-192beb4862f1 Q2 RICCHETTI INCORPORATED 62778 EISAI, INC. 2023 second_quarter PHA Issues related to coverage of Alzheimer's drugs and diagnostics under Federal health care programs; Issues related to drug pricing and access, and Medicare and Medicaid reimbursement; Issues related to pharmaceutical industry, generally HOUSE OF REPRESENTATIVES,SENATE 30000   0 0 2023-07-17T11:40:10-04:00
3006775 RICCHETTI INCORPORATED 3b2ae974-ff55-44ca-bea3-0d5d63eaff60 Q2 RICCHETTI INCORPORATED 62778 HORIZON THERAPEUTICS USA INC 2023 second_quarter PHA Issues related to pharmaceutical industry, generally; Issues related to drug pricing and access, and Medicare and Medicaid reimbursement HOUSE OF REPRESENTATIVES,SENATE 80000   0 0 2023-07-17T11:45:18-04:00
3006801 RICCHETTI INCORPORATED 0de0ec95-27b3-407e-a4d3-551d9ef2021d Q2 RICCHETTI INCORPORATED 62778 IPSEN BIOPHARMACEUTICALS, INC. 2023 second_quarter PHA Issues related to pharmaceutical industry, generally Issues related to development of products to treat limb spasticity and fibrodysplasia ossificans progressiva (FOP) HOUSE OF REPRESENTATIVES,SENATE 20000   0 0 2023-07-17T11:50:01-04:00
3006815 RICCHETTI INCORPORATED 9a6045ac-fac7-4d81-99aa-70b25598f8f6 Q2 RICCHETTI INCORPORATED 62778 NEUROCRINE BIOSCIENCES, INC. 2023 second_quarter PHA Issues related to pharmaceutical industry, generally HOUSE OF REPRESENTATIVES,SENATE 50000   0 0 2023-07-17T11:52:06-04:00
3006973 KEEFE STRATEGIES LLC (FKA KEEFE SINGISER PARTNERS) cf662790-b8ab-45e3-ae2d-d5d3842e55f9 Q2 KEEFE STRATEGIES LLC (FKA KEEFE SINGISER PARTNERS) 401105192 CVS HEALTH 2023 second_quarter PHA Issues encompassing general education regarding the pharmacy benefit manager/pharmacy industry. Issues related to access and affordability of healthcare, prescription drugs, and generic drugs. HOUSE OF REPRESENTATIVES,SENATE 30000   0 0 2023-07-17T12:56:34-04:00
3007129 KOUNTOUPES DENHAM CARR & REID, LLC d7c40bc3-2d88-45ac-9bc6-bfebc569ad6a Q2 KOUNTOUPES DENHAM CARR & REID, LLC 320918 CONSUMER HEALTHCARE PRODUCTS ASSOCIATION 2023 second_quarter PHA General issues related to over-the-counter pharmaceutical supply chain. HOUSE OF REPRESENTATIVES,SENATE 50000   0 0 2023-07-17T13:47:14-04:00
3007297 KOUNTOUPES DENHAM CARR & REID, LLC bb7ed993-72a4-4a78-9139-22f1247988aa Q2 KOUNTOUPES DENHAM CARR & REID, LLC 320918 CVS HEALTH 2023 second_quarter PHA Issues related to drug pricing transparency and COVID-19 testing, vaccination and treatment. H.R. 1770, the Equitable Community Access to Pharmacist Services Act. HOUSE OF REPRESENTATIVES,SENATE 80000   0 0 2023-07-17T14:25:42-04:00
3007667 TARPLIN, DOWNS & YOUNG, LLC a820664a-2958-4f3d-9b17-759e35c562c4 Q2 TARPLIN, DOWNS & YOUNG, LLC 304736 HEALTHCARE DISTRIBUTION ALLIANCE (HEALTHCARE DISTRIBUTION MANAGMENT ASSN.) 2023 second_quarter PHA Opioid Abuse - General issues related to opioid abuse and access to medication assisted treatment HR 501 Halt, Block, and Suspend Suspicious Orders HR 467 HALT Fentanyl Act HR 1770 - Equitable Community Access to Pharmacist Services Act Implementation of Public Law 113-54 (DSCSA) Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE,White House Office 80000   0 0 2023-07-17T15:25:14-04:00
3007707 WAXMAN STRATEGIES ba87825b-c6a2-46c0-97c8-91306a9a93aa Q2 WAXMAN STRATEGIES 401103693 340B HEALTH 2023 second_quarter PHA Issues affecting the 340B drug pricing program; Appropriations for 340B program. HOUSE OF REPRESENTATIVES,SENATE 45000   0 0 2023-07-17T15:34:29-04:00
3008233 STUMPTOWN STRATEGIES 908e37a5-d53b-4e94-b77b-9e464def28d2 Q2 STUMPTOWN STRATEGIES 401106433 PRIME THERAPEUTICS 2023 second_quarter PHA Introduction to Prime to new Members of the 118th Congress Monitoring PBM Legislation (bill numbers not yet finalized) HOUSE OF REPRESENTATIVES,SENATE 20000   0 0 2023-07-17T18:14:21-04:00
3008401 PANNONE LOPES DEVEREAUX & O'GARA LLC 0b456173-b78f-4628-a9eb-c1ecb7c0f937 Q2 PANNONE LOPES DEVEREAUX & O'GARA LLC 401105501 AMGEN 2023 second_quarter PHA Prescription drug pricing.   9000   0 0 2023-07-17T19:31:38-04:00
3008932 THE CONSILIO GROUP 2aeb659f-d305-4a4f-9143-123e175c6e33 Q2 THE CONSILIO GROUP 400374717 PARATEK PHARMACEUTICALS 2023 second_quarter PHA Development and commercialization of novel life-saving therapies for life-threatening diseases and other public health threats for civilian, government, and military use Air Force, Dept of,Defense, Dept of (DOD),HOUSE OF REPRESENTATIVES,SENATE,U.S. Secret Service,White House Office 36000   0 0 2023-07-18T09:26:18-04:00
3009109 BUCHANAN INGERSOLL & ROONEY PC 36288351-bfcc-44ca-92a4-1b16d9efc17c Q2 BUCHANAN INGERSOLL & ROONEY PC 55291 AIM IMMUNOTECH INC. 2023 second_quarter PHA Strategy development and implementation of company's federal government relations initiatives relating to research and development of therapeutics. Work with Department of Defense on Ebola countermeasures. Comprehensive Access to Resources and Education (CARE) For Long COVID Act Defense, Dept of (DOD),HOUSE OF REPRESENTATIVES,SENATE 20000   0 0 2023-07-18T09:50:21-04:00
3009245 CONSUMER HEALTHCARE PRODUCTS ASSOCIATION 17304f11-a333-4519-b9e9-74e57c94f487 Q2 CONSUMER HEALTHCARE PRODUCTS ASSOCIATION 29403 CONSUMER HEALTHCARE PRODUCTS ASSOCIATION 2023 second_quarter PHA OTC Switch - general advocacy on Prescription to Over-the-Counter Switch of medications and ingredients. Proposed rule for Nonprescription Drug Product with an Additional Condition for Nonprescription Use The Wastewater Infrastructure Pollution Prevention and Environmental Safety Act or the WIPPES Act -- not yet introduced. FDA Nonprescription Drugs Advisory Committee Meeting on Phenylephrine Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE 171093   0 0 2023-07-18T10:17:34-04:00
3009440 WATKINS & EAGER PLLC 61d4f7d6-e612-410d-a2a7-9a3258b99a3c Q2 WATKINS & EAGER PLLC 401104403 ZYNERBA PHARMACEUTICALS, INC. 2023 second_quarter PHA Encourage Members to act favorably on matters of importance to Zynerba at their direction; Trial for medication that could help individuals with Fragile X Syndrome. HOUSE OF REPRESENTATIVES,SENATE 45000   0 0 2023-07-18T11:00:12-04:00
3009453 POWERS PYLES SUTTER & VERVILLE, P.C. 969ee106-f487-4914-94bd-8c06ab442b92 Q2 POWERS PYLES SUTTER & VERVILLE, P.C. 32008 NATIONAL ASSOCIATION OF SPECIALTY PHARMACY 2023 second_quarter PHA Pharmacy market competition. Commerce, Dept of (DOC),Federal Trade Commission (FTC),HOUSE OF REPRESENTATIVES,SENATE 120000   0 0 2023-07-18T11:03:25-04:00
3009652 HEALTHSPERIEN 816ed45f-fff3-4cf9-bd70-27b5725da4f3 2A HEALTHSPERIEN 401103150 EXACT CARE PHARMACY 2023 second_quarter PHA Advocate for codifying definition for long-term care pharmacy. (S. 1574) Advocate for inclusion of chronic care pharmacy in CMS and CMMI payment approaches Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,SENATE 40000   0 0 2023-07-18T11:27:16-04:00
3010107 BURRELL INTERNATIONAL GROUP LLC 8c138b03-ef60-43bf-98ce-96b3c5932b22 Q2 BURRELL INTERNATIONAL GROUP LLC 401103483 ACER THERAPEUTICS 2023 second_quarter PHA COVID-19 therapeutics and Medical Countermeasures, Rare Disease, and Re-purposed drugs; Defense Appropriations for MCM Development HOUSE OF REPRESENTATIVES,SENATE 20000   0 0 2023-07-18T12:52:00-04:00
3010145 ALPINE GROUP PARTNERS, LLC. f9651e0f-e5eb-41c4-9bd7-0d66b9b58554 2T ALPINE GROUP PARTNERS, LLC. 1171 MINDBLOOM, INC. 2023 second_quarter PHA Telehealth legislation and regulation Mental health policy HOUSE OF REPRESENTATIVES,SENATE 70000   0 1 2023-07-18T13:00:13-04:00
3010149 AMERICAN PHARMACISTS ASSOCIATION 4e731395-b33f-443c-88c8-3166168d89b1 Q2 AMERICAN PHARMACISTS ASSOCIATION 3071 AMERICAN PHARMACISTS ASSOCIATION 2023 second_quarter PHA Provider status HOUSE OF REPRESENTATIVES,SENATE   35000 0 0 2023-07-18T13:00:28-04:00
3010167 340B HEALTH 34e57209-0d03-4007-9d59-3077e7151754 Q2 340B HEALTH 316434 340B HEALTH 2023 second_quarter PHA The 340B Drug Pricing Program; The Protect 340B Act; FY24 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations bill. HR 3290,to amend title III of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program. H.R.3561 - PATIENT Act of 2023 Centers For Medicare and Medicaid Services (CMS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,SENATE   360515 0 0 2023-07-18T13:06:22-04:00
3010168 BURRELL INTERNATIONAL GROUP LLC db5b1850-f0d0-4efe-9642-c597dec26fe4 Q2 BURRELL INTERNATIONAL GROUP LLC 401103483 TONIX PHARMACEUTICALS HOLDING CORP. 2023 second_quarter PHA LHHS Appropriation R&D Funding, Pandemic Preparedness Funding for Next Generation Products HOUSE OF REPRESENTATIVES,SENATE 40000   0 0 2023-07-18T13:06:28-04:00
3010188 BURRELL INTERNATIONAL GROUP LLC fbec5cf1-1278-4666-9c22-25b1187a3a1e Q2 BURRELL INTERNATIONAL GROUP LLC 401103483 SHIONOGI INC. 2023 second_quarter PHA Pandemic and All Hazards Preparedness Act, FY24 LHHS Funding for MCM Development HOUSE OF REPRESENTATIVES,SENATE 30000   0 0 2023-07-18T13:08:03-04:00
3010227 LINCOLN PARK GROUP L.L.C. ba0a690a-c6b3-4fe6-9bcf-eb048203c8ea Q2 LINCOLN PARK GROUP L.L.C. 401104374 CANADIAN INTERNATIONAL PHARMACY ASSOCIATION 2023 second_quarter PHA Issues related to importation of medicines for personal use. HOUSE OF REPRESENTATIVES,SENATE 40000   0 0 2023-07-18T13:14:42-04:00
3010289 DA VINCI GROUP 53a770de-a6fd-453a-843e-a740478d3381 Q2 DA VINCI GROUP 11548 BOESEN & SNOW, LLC 2023 second_quarter PHA Health Care Issues and pharmaceutical-related issues, generally; No Specific legislation during this period. HOUSE OF REPRESENTATIVES,SENATE 10000   0 0 2023-07-18T13:23:41-04:00
3010320 HANCE SCARBOROUGH a594db2f-d9fd-463e-ad4f-7f77f38b21a0 Q2 HANCE SCARBOROUGH 17443 ALLIANCE FOR PHARMACY COMPOUNDING 2023 second_quarter PHA Issues related to the regulation of pharmacy compounding. Issues related to preserving patient access to compounded medications. Fiscal Year 2024 Appropriations HR167, the Patient Access to Urgent Use Compounded Medication Act HOUSE OF REPRESENTATIVES,SENATE 50000   0 0 2023-07-18T13:34:02-04:00
3010360 SQUIRE PATTON BOGGS 246f2254-7800-426f-9309-7ba6bb6aff8d Q2 SQUIRE PATTON BOGGS 30906 SK HYNIX AMERICA, INC. 2023 second_quarter PHA Monitor proposals and issues related to biopharmaceuticals. HOUSE OF REPRESENTATIVES,SENATE 110000   0 0 2023-07-18T13:42:44-04:00
3010668 MEHLMAN CONSULTING, INC. 38721f94-9c39-4b68-a6a1-17ed4dff9038 Q2 MEHLMAN CONSULTING, INC. 284950 THE CAMPAIGN FOR SUSTAINABLE RX PRICING 2023 second_quarter PHA Prescription drug pricing issues. Pricing of Covid 19 vaccines. H.R. 485 - the Protecting Health Care for All Patients Act. S. 775 - Increasing Transparency in Generic Drug Applications Act. S. 1214 - Retaining Access and Restoring Exclusivity Act. S. 1067 - Ensuring Timely Access to Generics Act. S. 935 - Fair Accountability and Innovative Research Drug Pricing Act of 2023. Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE 50000   0 0 2023-07-18T14:24:02-04:00
3010819 E3 STRATEGIC CONSULTING GROUP 4f067cc8-96fd-4dde-86ad-ccbc186f25a2 Q2 E3 STRATEGIC CONSULTING GROUP 401104104 PHARMACEUTICAL INDUSTRY LABOR MANAGEMENT ASSOCIATION 2023 second_quarter PHA Prescription drug industry issues relating to domestic construction and maintenance, prescription drug pricing, and employment issues, generally; S.127 - Pharmacy Benefit Manager Transparency Act of 2023; S.113 - Prescription Pricing for the People Act of 2023; H.R.830 - HELP Copays Act; S. 1542 - Delinking Revenue from Unfair Gouging Act (a/k/a The DRUG Act"). HOUSE OF REPRESENTATIVES,SENATE 20000   0 0 2023-07-18T14:41:44-04:00
3010974 HB STRATEGIES 075c4aac-89a5-4b3a-9076-f4fecc7513a8 Q2 HB STRATEGIES 401104718 BAYER U.S. LLC 2023 second_quarter PHA Provide lobbying support of key issues and track relevant federal policy developments that could impact the pharmaceutical, healthcare and agricultural industries generally and Bayer specifically. HOUSE OF REPRESENTATIVES,SENATE 60000   0 0 2023-07-18T15:01:40-04:00
3011089 WINNING STRATEGIES WASHINGTON c4288008-e13a-4f59-83c7-8d42de0d8fa7 Q2 WINNING STRATEGIES WASHINGTON 50796 KALEO 2023 second_quarter PHA Pharmaceutical drug development, including epinephrine for anaphylaxis; drug access and affordability issues HOUSE OF REPRESENTATIVES,SENATE 10000   0 0 2023-07-18T15:13:15-04:00
3011220 DESIMONE CONSULTING, LLC 955dec8e-f38e-4b1d-8cd5-658f399dd4fe Q2 DESIMONE CONSULTING, LLC 400931695 PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA (PHRMA) 2023 second_quarter PHA Issues related to patient access and pricing. Issues related to policy changes to Medicare Part D. Issues related to PBM reform. HOUSE OF REPRESENTATIVES,SENATE 40000   0 0 2023-07-18T15:26:12-04:00
3011313 TRUSYNERGY 41a9886f-9576-4cf0-97e1-41b4bc6d1b28 Q2 TRUSYNERGY 401107715 BURRELL INTERNATIONAL GROUP LLC (ON BEHALF OF SHIONOGI INC.) 2023 second_quarter PHA Oversight of the Strategic National Stockpile to promote safer and more effective treatments in the stockpile; PASTEUR Act; reauthorization of the Pandemic and All Hazards Preparedness Act; FY 24 LHHS appropriations; funding and incentives for MCM development; AMR issues HOUSE OF REPRESENTATIVES,SENATE 10000   0 0 2023-07-18T15:35:51-04:00
3011387 DENTONS US LLP 4f8ff701-a57f-4f10-8498-a26d91fa59eb Q2 DENTONS US LLP 36105 PHARMACEUTICAL INDUSTRY LABOR MANAGEMENT ASSOCIATION (PILMA 2023 second_quarter PHA Federal issues impacting workforce and innovation in the pharmaceutical industry. HOUSE OF REPRESENTATIVES,SENATE 50000   0 0 2023-07-18T15:47:30-04:00
3011515 HANCE SCARBOROUGH 784dfdf7-297c-4a63-8579-e8bb5c7134ad Q2 HANCE SCARBOROUGH 17443 BOEHRINGER INGELHEIM USA CORPORATION 2023 second_quarter PHA Provide ongoing animal health policy monitoring, assessment, and research support. Telemedicine/telehealth legislation. HOUSE OF REPRESENTATIVES,SENATE 20000   0 0 2023-07-18T16:16:23-04:00
3011711 HANCE SCARBOROUGH d5f4ba8f-31ee-491b-aa4f-96bdc2c0df9b Q2 HANCE SCARBOROUGH 17443 PHRMA 2023 second_quarter PHA Patent reform regarding pharmaceutical research & products. SENATE     0 0 2023-07-18T16:57:24-04:00
3011872 ARENTFOX SCHIFF LLP 5c098719-7de8-4e69-8a94-921269cb3886 Q2 ARENTFOX SCHIFF LLP 4208 AMERICAN PHARMACY COOPERATIVE, INC. 2023 second_quarter PHA Prescription drug pricing generally HOUSE OF REPRESENTATIVES,SENATE 30000   0 0 2023-07-18T17:36:45-04:00
3011993 BLUE SHIELD OF CALIFORNIA 7fc25e87-49d8-4b0c-8fe4-edb6498a65e5 Q2 BLUE SHIELD OF CALIFORNIA 6518 BLUE SHIELD OF CALIFORNIA 2023 second_quarter PHA Matters related to pharmacy benefit manager reform. HOUSE OF REPRESENTATIVES,SENATE   110000 0 0 2023-07-18T18:21:56-04:00
3012004 BROWNSTEIN HYATT FARBER SCHRECK, LLP bcd3ded5-9476-4ccb-ad34-5003103db7de Q2 BROWNSTEIN HYATT FARBER SCHRECK, LLP 7257 WALGREEN CO. 2023 second_quarter PHA Pharmacist provider status Issues related to drug pricing Implementation of the Inflation Reduction Act of 2022 INFORM Act Issues related to access and distribution of pharmaceutical products HOUSE OF REPRESENTATIVES,SENATE 60000   0 0 2023-07-18T18:30:42-04:00
3012309 CAPITOL COUNSEL LLC c75126c5-2e91-4581-9b3c-c51ba8326277 Q2 CAPITOL COUNSEL LLC 313715 EMD SERONO, INC. 2023 second_quarter PHA Issues regarding the availability and pricing of prescription drugs. HOUSE OF REPRESENTATIVES,SENATE 50000   0 0 2023-07-18T21:15:29-04:00
3012387 PRIME POLICY GROUP ade8a9ac-ade3-4aa2-a9c1-c2d9bc373b63 Q2 PRIME POLICY GROUP 400532589 NATIONAL ASSOCIATION OF CHAIN DRUG STORES 2023 second_quarter PHA HR 1770 - Equitable Community Access to Pharmacist Services Act; PBM reform; PREP Act authorities HOUSE OF REPRESENTATIVES,SENATE,White House Office 80000   0 0 2023-07-18T21:47:24-04:00
3012635 PRIME POLICY GROUP e1bca7cf-0aa5-4a52-8899-abeb5c25ebee 2A PRIME POLICY GROUP 400532589 NATIONAL ASSOCIATION OF CHAIN DRUG STORES 2023 second_quarter PHA HR 1770 - Equitable Community Access to Pharmacist Services Act; PBM reform; PREP Act authorities HOUSE OF REPRESENTATIVES,SENATE,White House Office 80000   0 0 2023-07-18T23:03:33-04:00
3012958 VAN SCOYOC ASSOCIATES dc0f7546-b1c6-4009-8ebd-605493305cb7 Q2 VAN SCOYOC ASSOCIATES 39837 ZEBRA TECHNOLOGIES CORP. 2023 second_quarter PHA H.R.2670, National Defense Authorization Act for Fiscal Year 2024, Temperature monitoring technology Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, FY2024, Temperature monitoring related issues HOUSE OF REPRESENTATIVES,SENATE 30000   0 0 2023-07-19T06:54:10-04:00
3013057 ARNOLD & PORTER KAYE SCHOLER LLP d4a84497-d5c6-4c95-9750-c4cdb88375f5 Q2 ARNOLD & PORTER KAYE SCHOLER LLP 4301 NOVO NORDISK, INC. 2023 second_quarter PHA Issues related to pharmacy benefit managers and the 340B Program. HOUSE OF REPRESENTATIVES,SENATE 50000   0 0 2023-07-19T07:59:48-04:00
3013441 ELI LILLY AND COMPANY cece17f6-aebe-449f-befd-6bcb8c406986 Q2 ELI LILLY AND COMPANY 13392 ELI LILLY AND COMPANY 2023 second_quarter PHA Hospital discounts; 340B program HOUSE OF REPRESENTATIVES,SENATE   1585000 0 0 2023-07-19T09:28:21-04:00
3013484 KING & SPALDING LLP 40c60cbb-46e9-430e-b5be-0327eef5f1cf Q2 KING & SPALDING LLP 21632 SUMITOMO PHARMA AMERICA (FORMERLY SUNOVION PHARMACEUTICALS, INC.) 2023 second_quarter PHA Advocacy on low income subsidy benefits HOUSE OF REPRESENTATIVES,SENATE 60000   0 0 2023-07-19T09:39:16-04:00
3013600 CARD & ASSOCIATES, LLC 89e516fb-73a1-4962-9dd6-79730b1981b1 Q2 CARD & ASSOCIATES, LLC 84217 AMAZON.COM (FRA PILLPACK AN AMAZON COMPANY) 2023 second_quarter PHA Monitor legislation on drug price transparency and market access issues including legislative proposals related to drug pricing Monitor FY 2024 Appropriations Support access to telehealth Monitor and engage on EU digital regulatory policies HOUSE OF REPRESENTATIVES,SENATE 50000   0 0 2023-07-19T10:04:38-04:00
3013677 THE ALS ASSOCIATION f9e61ef5-ab9a-4915-8a2e-b3716a095aa4 Q2 THE ALS ASSOCIATION 401104947 THE ALS ASSOCIATION 2023 second_quarter PHA Promising Pathways Act (S.1906) - Discussion around a provisional approval path for drugs and biological interventions that meet unmet needs of rare diseases like ALS. HOUSE OF REPRESENTATIVES,SENATE   25000 0 0 2023-07-19T10:13:29-04:00
3013846 NELSON MULLINS RILEY & SCARBOROUGH ef200c5f-3ba4-48b6-aae6-c343ba7e2df4 Q2 NELSON MULLINS RILEY & SCARBOROUGH 285871 TIDELANDS HEALTH 2023 second_quarter PHA Issues related to the 340B Drug Pricing Program SENATE 50000   0 0 2023-07-19T10:33:53-04:00
3013864 NELSON MULLINS RILEY & SCARBOROUGH a0365158-ccca-4fbb-9edc-012cf1b8eb26 Q2 NELSON MULLINS RILEY & SCARBOROUGH 285871 HEMOPHILIA OF GEORGIA 2023 second_quarter PHA 340B Drug Pricing Program, patient co-pays legislation (H.R. 830) HOUSE OF REPRESENTATIVES,SENATE 20000   0 0 2023-07-19T10:35:10-04:00
3013986 BROWN & FORTUNATO, P.C. 2fa248be-9bf2-4ed4-8c7f-e170c4b0df5d Q2 BROWN & FORTUNATO, P.C. 401104878 PROMPTCARE COMPANIES, INC. 2023 second_quarter PHA Issues related to Medicare home infusion therapy benefit and other health care issues. Issues related to the Medicare DMEPOS competitive bidding program and Medicare coverage and payment for non-invasive ventilators. Centers For Medicare and Medicaid Services (CMS) 10000   0 0 2023-07-19T10:47:30-04:00
3013995 BLUE CROSS BLUE SHIELD OF MICHIGAN 2516e0eb-4ef2-4393-9185-024657e6ace9 Q2 BLUE CROSS BLUE SHIELD OF MICHIGAN 46676 BLUE CROSS BLUE SHIELD OF MICHIGAN 2023 second_quarter PHA Insulin Out of Pocket Charges; Finance PBNM Framework Proposals; S. 150 - Affordable Prescriptions for Patients Act of 2023 bill to amend the Federal Trade Commission Act to prohibit product hopping, and for other purposes. Sponsor: Sen. John Cornyn (R-TX) S. 127 - Pharmacy Benefit Manager Transparency Act of 2023 bill to prevent unfair and deceptive acts or practices and the dissemination of false information related to pharmacy benefit management services or prescription drugs, and for other purposes. Sponsor: Sen. Maria Cantwell (D-WA) S. 1067 - Ensuring Timely Access to Generics Act of 2023 o amend the Federal Food, Drug, and Cosmetic Act with respect to citizen petitions. Sponsor: Sen. Shaheen, Jeanne [D-NH] S. 1114 - Expanding Access to Low-Cost Generics Act of 2023 o amend the Federal Food, Drug, and Cosmetic Act with respect to the 180-day exclusivity period. Sponsor: Sen. Smith, Tina [D-MN] S. 1269 - INSULIN Act of 2023 o reduce the price of insulin and provide for patient protections with respect to the cost of insulin. Sponsor: Sen. Shaheen, Jeanne [D-NH] S. 1339 - Pharmacy Benefit Manager Reform Act o provide for increased oversight of entities that provide pharmacy benefit management services on behalf of group health plans and health nsurance coverage. Sponsor: Sen. Sanders, Bernard [I-VT] HOUSE OF REPRESENTATIVES,SENATE   269075 0 0 2023-07-19T10:47:49-04:00
3014388 AMERICAN VETERINARY MEDICAL ASSOCIATION 16b858f6-4220-44c7-98a6-9f74a4877546 Q2 AMERICAN VETERINARY MEDICAL ASSOCIATION 3630 AMERICAN VETERINARY MEDICAL ASSOCIATION 2023 second_quarter PHA H.R. 1418/ S. 1844 Animal Drug User Fee Act/ Animal Generic Drug User Fee Act reauthorization H.R. 1839/S. 993 Combatting Illicit Xylazine Act Review of Food and Drug Administrations Final Guidance for industry #256: Compounding Animal Drugs from Bulk Drug Substances- H.R. 1683 Generic Animal Drug Advancement Act, all provisions Executive Office of the President (EOP),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Justice, Dept of (DOJ),SENATE   330000 0 0 2023-07-19T11:17:12-04:00
3014673 BUCHANAN INGERSOLL & ROONEY PC 524765e7-fb25-4e2f-b15d-cf63a82e9d8c Q2 BUCHANAN INGERSOLL & ROONEY PC 55291 FERA PHARMACEUTICALS, LLC 2023 second_quarter PHA Strategy development and implementation of federal government relations initiatives relating to phospholine iodide issues with the Food and Drug Administration and Centers for Medicare and Medicaid Services. Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE     0 0 2023-07-19T11:37:56-04:00
3014926 BUCHANAN INGERSOLL & ROONEY PC 5e48f4cd-493f-4f73-b620-868377f4dd46 Q2 BUCHANAN INGERSOLL & ROONEY PC 55291 GENERIC ANIMAL DRUG ALLIANCE 2023 second_quarter PHA Strategy development and implementation of federal government relations initiatives relating to generic animal drug industry. H.R. 1683, the Generic Animal Drug Advancement Act, all provisions; H.R. 1418, the Animal Drug User Fee Amendments of 2023, all provisions Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE 30000   0 0 2023-07-19T12:04:46-04:00
3015144 NATIONAL RIGHT TO LIFE COMMITTEE 4ea57e6f-15cf-4e8f-88ec-31d86730b1af Q2 NATIONAL RIGHT TO LIFE COMMITTEE 28481 NATIONAL RIGHT LIFE COMMITTEE 2023 second_quarter PHA Contacts in support of proposed rule, "Telemedicine Prescribing of Controlled Substances When the Practitioner and the Patient Have Not Had a Prior In-Person Medical Evaluation," 88 FR 12875 (March 1, 2023), (RIN): 1117-AB40, Docket ID DEA-407 due to impact of assisted suicide drugs. Contacts regarding vending machine dispensing of chemical abortion drugs. Drug Enforcement Administration (DEA),SENATE   80000 0 0 2023-07-19T12:25:17-04:00
3015164 BLUECROSS BLUESHIELD OF TENNESSEE ba8694da-4d69-49e9-b422-853fec910351 Q2 BLUECROSS BLUESHIELD OF TENNESSEE 6440 BLUECROSS BLUESHIELD OF TENNESSEE 2023 second_quarter PHA Insulin Act; Insulin Out of Pocket Charges; Pharmacy Benefit Managers; Delinking PBM language S 954 - Affordable Insulin Now Act A bill to provide for appropriate cost-sharing for insulin products covered under private health plans and to establish a program to support health care providers and pharmacies in providing discounted insulin products to uninsured individuals. S. 1339 - Pharmacy Benefit Manager Reform Act To provide for increased oversight of entities that provide pharmacy benefit management services on behalf of group health plans and health insurance coverage S.127 - PBM Transparency Act of 2023 To prevent unfair and deceptive acts or practices and the dissemination of false information related to PBM services for Rx drugs, etc. HOUSE OF REPRESENTATIVES,SENATE   150000 0 0 2023-07-19T12:28:49-04:00
3015378 WAKE FOREST BAPTIST MEDICAL CENTER AFFILIATE OF ADVOCATE HEALTH db79759c-915f-4a3c-a670-b7bcf68f9431 Q2 WAKE FOREST BAPTIST MEDICAL CENTER AFFILIATE OF ADVOCATE HEALTH 401107274 WAKE FOREST BAPTIST MEDICAL CENTER AFFILIATE OF ADVOCATE HEALTH 2023 second_quarter PHA any bills or provisions related to the 340b drug discount program HOUSE OF REPRESENTATIVES   30589 0 0 2023-07-19T12:50:17-04:00
3015412 FAEGRE DRINKER BIDDLE & REATH LLP ddd7cd43-5a1d-44fa-b5fd-3e6377da1056 Q2 FAEGRE DRINKER BIDDLE & REATH LLP 12631 NATIONAL ASSOCIATION OF BOARDS OF PHARMACY 2023 second_quarter PHA Medication safety, pharmacy regulation and licensure, drug supply chain security, and combatting the opioid epidemic; Prescription drug monitoring programs; HR 501 Block, Report, and Suspend Suspicious Shipments Act; Ryan Haight Act/DEA rule on telehealth. Drug Enforcement Administration (DEA),Executive Office of the President (EOP),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Justice, Dept of (DOJ),SENATE 30000   0 0 2023-07-19T12:53:01-04:00

Next page

Advanced export

JSON shape: default, array, newline-delimited, object

CSV options:

CREATE TABLE lobbying_activities (
            id INTEGER PRIMARY KEY,
            filing_uuid TEXT NOT NULL,
            filing_type TEXT NOT NULL,
            registrant_name TEXT NOT NULL,
            registrant_id INTEGER,
            client_name TEXT NOT NULL,
            filing_year INTEGER NOT NULL,
            filing_period TEXT NOT NULL,
            issue_code TEXT,
            specific_issues TEXT,
            government_entities TEXT,
            income_amount INTEGER,
            expense_amount INTEGER,
            is_no_activity INTEGER DEFAULT 0,
            is_termination INTEGER DEFAULT 0,
            received_date TEXT,
            CONSTRAINT fk_activity_filing FOREIGN KEY (filing_uuid)
                REFERENCES lobbying_filings_raw(filing_uuid)
        );
CREATE INDEX idx_act_client_name ON lobbying_activities(client_name COLLATE NOCASE);
CREATE INDEX idx_act_issue_code ON lobbying_activities(issue_code);
CREATE INDEX idx_act_filing_year ON lobbying_activities(filing_year);
CREATE INDEX idx_act_filing_uuid ON lobbying_activities(filing_uuid);
Powered by Datasette · Queries took 2084.58ms · Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API